<DOC>
	<DOCNO>NCT01167777</DOCNO>
	<brief_summary>Multicenter clinical study test new qualitative vitro nucleic acid amplification assay base kPCR technology . The assay intend diagnosis Chlamydia trachomatis ( CT ) Neisseria gonorrhoeae ( GC ) .</brief_summary>
	<brief_title>Multi-center Evaluation VERSANTÂ® CT/GC DNA 1.0 Assay ( kPCR ) Detecting C. Trachomatis N. Gonorrhoeae</brief_title>
	<detailed_description>The study terminate This clinical trial protocol outline analytical clinical performance characteristic evaluate demonstrate equivalency VERSANT CT/GC DNA 1.0 ( kPCR ) Assay product registration . The Gen-Probe APTIMA Combo 2 Assay use CE-marked comparative method . The study conduct clinical trial intend provide data support safety effectiveness , well label claim VERSANT CT/GC Assay . The study objectives follow : - To demonstrate concordance Gen-Probe APTIMA Combo 2 Assay ; - To estimate positive negative predictive value specimen type include study ; - To estimate indeterminate rate specimen type include study ; - To estimate equivocal rate specimen type ; - To assess reproducibility VERSANT CT/CG DNA 1.0 Assay ( kPCR ) use VERSANT kPCR Molecular System . Two ( 2 ) study conduct validate analytical clinical performance characteristic CT/GC DNA 1.0 ( kPCR ) Assay . Table 1 provide overview study .</detailed_description>
	<mesh_term>Chlamydia Infections</mesh_term>
	<mesh_term>Gonorrhea</mesh_term>
	<criteria>Subject 18 year age old . Subject sign IRB approve informed consent form . Subject able follow verbal write instruction . Subject antibiotic therapy within 21 day prior study enrollment . Subject urinate within one hour prior sample collection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>CT</keyword>
	<keyword>GC</keyword>
	<keyword>NG</keyword>
	<keyword>chlamydia</keyword>
	<keyword>gonorrhoeae</keyword>
</DOC>